الفهرس | Only 14 pages are availabe for public view |
Abstract Renal cell carcinoma (RCC) is the commonest histologic subtype of renal tumors accounting for about 85%. Globally it accounts for3% of all malignancies in adult. In Egypt, Kidney cancer represent about 11% of malignancies of urinary system and 1.78% of total malignancies with RCC accounting for more than 60% of them. Up to 30% of organ confined RCC develop metastasis or recurrence during follow up time. Also, due to asymptomatic nature of the disease, about 17% of cases are diagnosed at advanced stage with very limited therapeutic modalities and short over-all survival. Thus, there is an urgent need to identify specific biomarkers that can be used for early diagnosis, prognosis and to tailor treatment strategies for RCC patients. Some studied reported important role of STAT3-HIF1α pathway in development and progression of RCC. Therefore, targeting this pathway may represent a promising therapeutic modality for RCC patients. The aim of this study was to study the immunohistochemical expression results of pSTAT3, HIF1α and VEGF in RCC and correlate their expression with available clinicopathologic parameters and survival data. This retrospective case control study was conducted on 89 renal specimens including 58 cases of RCC, 14 cases end stage kidney (ESKD) and 17 cases of non-neoplastic tissue adjacent to tumors. All specimens were obtained from Egyptian patients. In this study a significant statistical difference could be detected between pSTAT3, HIF1α and VEGF expression in RCC and ESKD groups with a higher expression among RCC cases. |